The use of anabolic substances for growth promoting purposes in food producing animals 23 is prohibited within the EU, yet ongoing applications of hormones such as oestradiol 24 prove both difficult to detect and to distinguish from endogenous presence. Additionally, 25 the misuse of glucocorticoid compounds (dexamethasone and prednisolone), which are 26 permitted for therapeutic applications but can also promote improved animal health 27 through long-term dosing, is reported to be increasing posing potential health concerns 28 for consumers. Twenty-four male beef cattle were randomly assigned to four groups 29 (n=6) for experimental treatment over 40 days consisting of a control untreated group, 30 and three treatment groups administered oestradiol, dexamethasone or prednisolone at 31 levels known to reflect growth promoting practices. Untargeted metabolomic profiling of 32 plasma collected from each animal midway through the study treatment period, were 33 analysed by reverse phase separation employing an UHPLC-QTof-MS system operating in The focus of the current study has centred on the detection of metabolomic 134 markers significant to the misuse of glucocorticoid (dexamethasone and prednisolone) 135 and oestradiol compounds in bovine animals for meat enhancement purposes. (Table 1a and Galα1-3, GM3 were increased most by prednisolone administration in this study with 425 observable fold change differences ranging from 3-11 times the peak output from the The differing responses relative to the level of drug exposure is yet to be determined but 512 it is anticipated that further development of these gangliosides, lipoproteins, Co-enzyme 513 A, acylcarnitines and eicosanoids into rapid onsite screening tools could detect cases of 514 drug misuse prior to confirmatory analysis. TABLE 1a   798   799 TABLE 1b TABLE 2 803
